Aim: To investigate whether the stage of osteoarthritis (OA) progression influenced the efficacy of the third-generation bisphosphonate zoledronic acid in a rat medial meniscal tear model. Methods: Medial meniscal tear (MMT) was surgically induced in adult male Sprague Dawley rats. Zoledronic acid (ZOL, 100 μg/kg, sc, twice a week) was administered starting immediately, early (from 4 weeks) or late (from 8 weeks) after OA induction. The degeneration of articular cartilage was evaluated with toluidine blue O staining. Subchondral bone remodeling was evaluated with X-ray micro-CT scanning. Joint pain was measured with respect to weight-bearing asymmetry. Calcitonin gene-related peptide (CGRP) expression in dorsal root ganglia (DRGs) was examined using immunofluorescence analysis. The afferent neurons in DRGs innervating the joint were identified by retrograde labeling with fluorogold. Results: Progressive cartilage loss was observed during 12 weeks after OA induction. Subchondral bone remodeling manifested as increased bone resorption at early stage (4 weeks), but as increased bone accretion at advanced stages (8 weeks). Immediately and early ZOL administration significantly improved subchondral microstructural parameters, attenuated cartilage degeneration, reduced weight-bearing asymmetry and CGRP expression, whereas the late ZOL administration had no significant effects. Conclusion: The stage of OA progression influences the efficacy of ZOL in treating joint degeneration and pain. To obtain the maximum efficacy, bisphosphonate treatment should be initiated in rat with early stages of OA pathogenesis.
Introduction
Osteoarthritis (OA), a leading cause of disability in the elderly [1] , is characterized by a progressive loss of articular cartilage and abnormalities in subchondral bone and surrounding soft tissue adaptations [2] , with chronic pain being the main clinical symptom [3] . The search for effective agents that attenuate joint degeneration and relieve joint pain has been challenging.
For decades, articular cartilage has been the focus of major basic research and pharmaceutical therapies, although alterations in the subchondral bone were generally considered to occur secondary to cartilage degeneration [4, 5] . However, it is increasingly accepted that subchondral bone plays an important role in the pathogenesis of OA. Accumulating evidence from clinical and animal studies has demonstrated that during OA progression, subchondral bone turnover increases dramatically, with increased bone resorption occurring early, and increased bone accretion occurring later in the disease [6] [7] [8] . Meanwhile, the biochemical composition and biomechanical properties of the subchondral bone are altered [9, 10] . Therefore, because of an intimate biological and mechanical relationship with articular cartilage, the presence of abnormal subchondral bone influences the integrity of the overlying cartilage [11] [12] [13] . In addition, abnormalities in subchondral bone, such as exposure of the subchondral bone plate, bone attrition, and bone marrow lesions, have been associated with knee pain [14] [15] [16] [17] .
Consequently, targeting subchondral bone with bone-mod-ifying agents would be expected to retard joint degeneration and alleviate pain. Bisphosphonates, the most commonly used agents for osteoporosis treatment, are a promising therapy for OA because of their ability to inhibit osteoclastic bone absorption [18] . However, the ability of bisphosphonates to preserve the structural integrity of subchondral bone and attenuate cartilage degeneration that has been seen in animal studies has not been consistently confirmed by clinical data [19] [20] [21] [22] , which is in part attributed to deficiencies in evaluation criteria or experimental design. Subchondral bone properties are dynamic with disease progression. Therefore, patients with different stages of subchondral bone alterations could have been included in the studies and may have contributed to the inconsistent clinical findings. We hypothesized that the stage of disease progression, especially the stage of subchondral bone remodeling, could influence the efficacy of bisphosphonate therapy. Many animal models have been developed to experimentally reproduce OA. The most commonly used rat medial meniscal tear (MMT) model demonstrates dynamic subchondral bone changes. Therefore, the cartilage-and bonepreserving activities of therapeutic agents can be evaluated in this model [23] . Moreover, this model manifests changes in pain behavior, neuron phenotype and neuropeptide expression [24] [25] [26] , which, taken together, represent a model of the joint pain associated with OA. Therefore, in the present study, we used the established rat MMT model and initiated zoledronic acid (ZOL, a third-generation bisphosphonate) treatment at different stages after OA induction to evaluate the efficacy of ZOL treatment on joint degeneration and pain. Pain behavior, cartilage histology, subchondral microarchitecture, and the expression of calcitonin gene-related peptide (CGRP), a painrelated neuropeptide, in the dorsal root ganglia (DRG) were evaluated.
Materials and methods

Animals
Adult male Sprague Dawley rats (Sino-British Sippr/BK Lab Animal Ltd, Shanghai) weighing 296±12 g (mean±SD) were used for these experiments. Animals were group-housed on a 12-h light/dark cycle with food and water ad libitum. All experimental procedures were approved by the Animal Care and Experiment Committee of Shanghai Jiaotong University School of Medicine and were consistent with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Every effort was made to minimize the number of animals used and their suffering.
Induction of OA
After acclimatization for 1 week, rats were anesthetized with 10% chloral hydrate in phosphate buffered saline (PBS, 0.01 mol/L). The MMT model was induced as previously described [27] . Briefly, the medial collateral ligament of the right knee was transected, and the medial meniscus was reflected proximally toward the femur and cut through at its narrowest point. For the controls (Sham), the wounds were closed after exposing the medial collateral ligament.
Experimental design
A total of 154 animals were used for the present study. In the preliminary experiment, of the total number of animals used, 64 animals were used to observe the changes in cartilage and subchondral bone during OA progression. The animals were sacrificed at 2, 4, 8, and 12 weeks after OA induction (n=8 at each time point). Another 40 animals were used to confirm the positive effects of ZOL in the MMT model and to choose a dose of ZOL that better preserved subchondral bone. ZOL (Aclasta ® , Novartis Pharma Stein AG) was administered subcutaneously twice a week at low dose 10 μg/kg body weight (MMT/ZolL) and high dose 100 μg/kg body weight (MMT/ ZolH). The same volume of normal saline was given to the Sham animals (Sham/NS) and MMT control animals (MMT/ NS). The animals (n=10 per group) were sacrificed at 4 weeks after OA induction.
Based on the above results, ZOL treatment was initiated at three stages following OA induction: immediately (ZOL0), early (4 weeks, ZOL4) and late (8 weeks, ZOL8). ZOL was administered subcutaneously twice a week at 100 μg/kg body weight. The same volume of normal saline was given to the Sham animals (Sham/NS) and MMT control animals (MMT/ NS). All five groups of animals (n=10 per group) were sacrificed at 12 weeks following the induction of OA. The experimental design is shown as Scheme 1.
Pain behavior testing
Pain behavior was measured as weight-bearing asymmetry between the OA-induced (right) and contralateral (left) limb using an incapacitance meter (IITC Life Sciences, Woodland Hills, CA, USA) as previously described [24] . Briefly, rats were placed in an angulated Perspex container so that each hind paw rested on a separate transducer pad. The force exerted by each hind limb was averaged over a 5-s period. Each data point is the mean of three 5-s readings. Changes in weightbearing asymmetry were evaluated one day before and once a week after OA induction. The percentage of weight placed on the right hind limb was determined using the formula below [28] . Retrograde neuronal labeling Afferent neurons in DRGs innervating the joint were identified by retrograde labeling with fluorogold (FG). To this end, 5 μL of 2% FG (Sigma, 39286) in 0.1 mol/L PBS was injected intraarticularly into the right knee of an anesthetized rat using a 33-gauge needle and a Hamilton microsyringe one week prior to the end of the experiment [25] .
Tissue preparation
After anesthesia, rats were transcardially perfused with 250 mL of heparinized saline (10 IU/mL) followed by 300 mL of ice-cold, fresh 4% paraformaldehyde (PFA) in 0.1 mol/L PBS. Lumbar L3, L4, and L5 DRGs were harvested and fixed in 4% PFA for 3 h and then cryoprotected in 30% sucrose in 0.1 mol/L PBS overnight at 4 °C. DRGs were then sliced into 12-μm sections with every sixth section collected on the same glass slide and stored at -80 °C. The entire knee joint was also dissected for histological and micro-CT imaging.
Micro-CT imaging and analysis
After fixation in 4% PFA for 48 h, the knee joints were scanned by X-ray microcomputed tomography (micro-CT) (μCT 80; SCANCO Medical AG) with an isotropic voxel resolution of 10 μm. A portion (2.0 mm ventrodorsal length) of the loadbearing region at the medial tibial plateau was identified as a region of interest. The following three-dimensional structural parameters were calculated: bone volume fraction (BV/TV), trabecular thickness (Tb.Th), trabecular spacing (Tb.Sp), trabecular number (Tb.N), and connectivity density (CD).
Histological analysis
After being imaged by micro-CT, the knee joints were decalcified in 10% EDTA for 3 weeks. The joints were bisected along the collateral ligament in the frontal plane, and both sections were embedded in the same paraffin block. The samples were cut into 5-μm sections. On the basis of the OARSI recommendations for the histological assessment of osteoarthritis in the rat [23] 
Statistical analysis
All behavioral testing, micro-CT statistical analysis, cartilage scoring and neuron counting was performed by blinded authors who were unaware of the treatments given. The results are presented as the mean±standard deviation (SD). A comparison between groups was performed with one-way analysis of variance using the LSD post-hoc test. P values less than 0.05 were considered statistically significant.
Results
Generally, cartilage changes occurred and worsened in a timedependent manner between 2 and 12 weeks post OA induction (Figure 1 ). At 2 weeks, matrix and chondrocyte loss affected the superficial and upper middle zone, and at 4 weeks, these changes deepened into the deep zone and extended into more than 1/3 zone of the medial tibial plateau. Severe changes occurred at 8 weeks with full thickness degeneration into the tidemark, which become more widespread at 12 weeks. Subchondral bone structure of the medial tibial plateau showed dynamic alterations following OA induction from increased bone resorption at early stages (2 and 4 weeks) to increased bone accretion at advanced stages (8 and 12 weeks) ( Figure 2) . Compared with the Sham groups, BV/TV was significantly decreased at 2 and 4 weeks and increased at 8 and 12 weeks post-operation. These changes were accompanied by Tb.Th changing from thinner (2 and 4 weeks) to thicker (8 and 12 weeks), Tb.Sp from broader (2 and 4 weeks) to more narrow (8 and 12 weeks), and Tb.N and CD being reduced at all times. Compared with MMT/NS animals, cartilage matrix and chondrocyte loss were partly reversed in animals with ZOL administration at both doses, and additional efficacy was observed in the MMT/ZOLH group (Figure 3) . Abnormal microarchitecture parameters, such as the noticeably reduced BV/TV, Tb.N, Tb.Th, CD, and increased Tb.Sp seen in the MMT/NS group, were well preserved by high-dose ZOL treatment and partly preserved with low-dose therapy. In % of weight on right limb= weight on right limb ×100 weight on right limb+weight on left limb addition, marked osteosclerosis was observed at the tibial metaphysis in animals treated with ZOL, which was induced by ZOL inhibiting osteoclasts in the growth plate ( Figure 4 ).
Pain behavior
As shown in Figure 5 , there was a marked reduction in hind limb weight-bearing 1 week post-OA induction, which was almost completely resolved by 2 weeks in all of the groups. Subsequently, Sham/NS animals returned to normal weightbearing, whereas MMT animals (MMT/NS, MMT/ZOL0, MMT/ZOL4, MMT/ZOL8) experienced weight-bearing asymmetry that gradually became worse in a time-dependent manner. Compared with MMT/NS controls at any time point tested, rats that received early ZOL therapy showed less weight-bearing asymmetry (MMT/ZOL0 and MMT/ ZOL4) with an increased benefit observed in rats that received therapy immediately after OA induction. However, delayed administration of ZOL (MMT/ZOL8) did not yield a statistically significant difference. Specifically, 12 weeks post-OA induction, the MMT/ZOL0, MMT/ZOL4 and MMT/ZOL8 animals placed 45.21%±1.07% (P<0.01), 43.66%±1.39% (P<0.05) and 42.15%±1.25% (P>0.05), respectively, of their hind limb weight on the right leg compared with 41.97%±0.93% in the MMT/NS animals.
Articular cartilage degeneration
As indicated by toluidine blue O staining and cartilage degeneration scoring (Figure 6 ), widespread and profound cartilage matrix and chondrocyte loss were observed in MMT/NS animals at 12 weeks; however, this loss was significantly reduced by ZOL administration in MMT/ZOL0 animals and moderately reduced in MMT/ZOL4 animals. No statistically significant improvement was observed in the MMT/ZOL8 animals. Specifically, the cartilage degeneration score was 7.25±1.28 (P<0.01), 10.13±1.55(P<0.01), and 12.0±1.69 (P>0.05) for the MMT/ZOL0, MMT/ZOL4, and MMT/ZOL8 animals, respectively, compared with 12.13±1.55 for the MMT/NS animals.
Synovial reaction
The synovial reaction was evaluated based on the OARSIrecommended scoring system. As shown in Figure 7S and 8S, the synovial reaction was similar among all the groups. The synovial lining comprised only 1-2 layers of cells, and no inflammatory cell infiltration was observed.
Subchondral bone remodeling
Representative images of knee joints obtained from micro-CT scanning are shown in Figure 7B . Generally, MMT resulted in increased bone accretion and cyst formation at 12 weeks, whereas ZOL treatment reversed these changes in a stagedependent manner. The bone cysts observed in the MMT/NS animals were absent in the MMT/ZOL0 and MMT/ZOL4 animals and appeared to be smaller in the MMT/ZOL8 animals, although the size of the cysts was not quantified. In addition, marked osteosclerosis was present at the tibial metaphysis in animals treated with ZOL, which occurred as a result of ZOL treatment inhibiting osteoclasts in active growth plates. The analysis of subchondral bone microstructure indexes is shown in Figure 7C . Compared with the Sham/NS animals, the subchondral bone of the medial tibial plateau in MMT/ NS animals was significantly altered. The alterations included increased BV/TV, thickened Tb.Th, narrowed Tb.Sp, and 
CGRP expression in DRG neurons
As shown in Figure 8 , the total neuron number, as determined by fluorescent Nissl staining, was similar among all five groups (P>0.05). Retrograde labeling through intra-articular injection of FG allowed the tracing of afferent neurons that innervate the knee joint in L3, L4, and L5 DRGs. The total number of FG-labeled neurons was not significantly different among the groups (P>0.05 
Discussion
The present study demonstrated that cartilage degeneration and subchondral bone remodeling in the rat MMT model occurred in a time-dependent manner. With disease progression, subchondral bone remodeling shifted from increased bone resorption at an early stage to bone accretion at an advanced stage. These results were consistent with those of earlier published studies [8, 19] . Similar to previous studies [19, 29] , the current study showed that bisphosphonates demonstrated a protective effect on cartilage and bone changes related to OA in a dose-dependent manner. To better elucidate the timedependent effects of the therapy, the higher dose was chosen.
We found that immediate ZOL administration significantly, [10, 13, 22] , the abnormal remodeling of subchondral bone would aggravate the degeneration of overlying articular cartilage; thus, retarded bone remodeling would slow the degeneration of overlying articular cartilage [9, 11, 12] . However, because subchondral bone properties are dynamic during disease progression, the abnormal subchondral bone cannot always be modified. Our data demonstrated that subchondral bone absorption is increased at an early stage of OA. If ZOL treatment is initiated at this stage, abnormalities in subchondral bone can be reversed to a large extent and then cartilage degeneration would be retarded accordingly. Conversely, at an advanced stage, subchondral bone accretion was increased mainly due to excessive mechanical stress [30] [31] [32] . If ZOL therapy is given at this stage, subchondral bone remodeling would not be reversible, and articular cartilage degeneration would continue.
To better identify the effects of ZOL on joint pain, pain behavior was measured as weight-bearing asymmetry between operated and contralateral hind limbs, and the expression of CGRP in DRG neurons innervating the joint was measured. CGRP is a marker of sensory neurons expressed by C and Aδ primary afferent fibers and is mainly involved in pain perception [33] . It has been shown that nociceptive Aδ and C fibers innervate the capsule, ligaments, periosteum and subchondral bone of the joint [3] . Osteoarthritic conditions activate the nociceptive system, and CGRP is elevated in the DRGs [25, 34] . A decrease in the number of CGRP-positive DRG neurons was also consistent with improved pain behavior [25, 35] . In accordance with a previous study, our data show that the percentage of CGRP-positive neurons was markedly increased at advanced stages in the MMT model, whereas ZOL treatment initiated at early stages reduced the expression of CGRP. These findings, combined with the results of pain behavior studies, indicate that ZOL treatment initiated at an early stage could relieve joint pain.
Currently, the origin of pain in osteoarthritis is poorly understood. Synovitis has been found to be associated with knee pain severity [14, 17] . However, consistent with a previous study [24] , histological analysis of the MMT joint in the present study did not reveal any synovial hyperplasia (Figures 7S and 8S) . Hence, the weight-bearing asymmetry and increased CGRP expression after MMT surgery indicate that OA structural changes, rather than synovitis, cause joint pain. ZOL treatment initiated early, but not late, retards cartilage degeneration and subchondral bone remodeling, leading us to believe that ZOL reduces joint pain by inhibiting OA structural changes. Adult articular cartilage is normally an avascular tissue [3] ; therefore, abnormal subchondral bone may be the main source of algogenesis. This hypothesis is supported by findings that knee pain is correlated with abnormalities in subchondral bone [14] [15] [16] [17] and by the following findings. Osteochondral vascular density increased with increasing cartilage deterioration severity and clinical disease activity scores [36] . Sensory nerves were present within vascular channels at the osteochondral junction in OA [37] . Therefore subchondral nerves may be exposed to painful stimuli in OA, which would npg lead to weight-bearing pain, the most common symptom in OA patients [3] . Immediate pain relief is obtained by total or unicompartmental knee arthroplasty [38] , in which most of the affected subchondral plate is excised. Therefore, we hypothesize that the potential mechanism by which bisphosphonates reduce joint pain mainly lies in improving cartilage and subchondral bone integrity and accordingly inhibiting subchondral neurovascular invasion. However, other potential mechanisms may be involved. For example, the acidic environment created by osteoclasts could cause bone pain during subchondral bone remodeling [19, 39] . Nevertheless, weight-bearing asymmetry and CGRP expression were similar in MMT/NS rats and MMT/ZOL8 rats. However, subtle differences may be detected with a more sophisticated behavior apparatus, such as a computerized incapacitance meter system and gait analysis system, to measure neuron electrophysiology and detect additional neuropeptides in DRGs and the spinal cord.
In the present study, ZOL was phase-administered based In conclusion, our study demonstrated, using an established rat MMT OA model, that the stage of OA progression influences the efficacy of ZOL therapy on joint degeneration and pain. ZOL treatment initiated immediately, and to some degree early, significantly inhibited subchondral bone remodeling, attenuated cartilage degeneration, and alleviated joint pain; no statistically significant efficacy was observed if therapy was initiated at a later stage, when significant cartilage degeneration and subchondral bone accretion were already present. Similarly, to obtain the maximum efficacy, bisphosphonate treatment should be initiated in rat at an early stage of OA, rather than in individuals with advanced stages of OA pathogenesis.
